S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS

Authors :: F. Gay
C. Cerrato
D. Rota Scalabrini
A. Belotti
M. Galli
E. Zamagni
M. Offidani
P. Omedé
F. Monaco
P. Tosi
O. Annibali
F. Pisani
R. Troia
A. Pascarella
F. Ferrara
M. Cea
B. Dalla Palma
F. Patriarca
S. Aquino
A. Palmas
A. Siniscalchi
M. Grasso
A. Palumbo
A. Ledda
P. Musto
M. Cavo
M. Boccadoro
Source :: HemaSphere. 3:390-391
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
Risk status
medicine.medical_specialty
business.industry
Hematology
Newly diagnosed
Carfilzomib
Transplantation
chemistry.chemical_compound
chemistry
Internal medicine
medicine
business
Dexamethasone
medicine.drug
Lenalidomide

Full Text Access

Tools